🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 2 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/04/1992 | 6,00 | 6,00 | 5,63 | 5,81 | +3,33% | 6,25% | 25.600 |
| 10/04/1992 | 5,88 | 6,00 | 5,63 | 5,63 | +2,27% | 6,38% | 312.200 |
| 09/04/1992 | 5,69 | 5,75 | 5,50 | 5,50 | -2,22% | 4,40% | 38.000 |
| 08/04/1992 | 5,63 | 5,75 | 5,50 | 5,63 | +0,00% | 4,44% | 105.600 |
| 07/04/1992 | 5,88 | 6,00 | 5,63 | 5,63 | -4,26% | 6,38% | 86.000 |
| 06/04/1992 | 5,50 | 5,94 | 5,50 | 5,88 | +9,30% | 7,95% | 69.200 |
| 03/04/1992 | 5,88 | 5,88 | 5,31 | 5,38 | -6,52% | 9,57% | 1.459.000 |
| 02/04/1992 | 5,50 | 5,88 | 5,50 | 5,75 | +4,55% | 6,82% | 78.200 |
| 01/04/1992 | 5,88 | 5,88 | 5,50 | 5,50 | -6,38% | 6,38% | 17.400 |
| 31/03/1992 | 5,50 | 5,88 | 5,50 | 5,88 | +0,00% | 6,82% | 43.000 |
| 30/03/1992 | 5,75 | 5,88 | 5,38 | 5,88 | +9,30% | 8,70% | 1.024.800 |
| 27/03/1992 | 5,75 | 5,75 | 5,38 | 5,38 | +0,00% | 6,52% | 31.600 |
| 26/03/1992 | 6,00 | 6,00 | 5,38 | 5,38 | -6,52% | 10,42% | 66.200 |
| 25/03/1992 | 5,75 | 6,00 | 5,75 | 5,75 | +0,00% | 4,35% | 14.200 |
| 24/03/1992 | 5,88 | 6,13 | 5,75 | 5,75 | -4,17% | 6,38% | 95.600 |
| 23/03/1992 | 5,88 | 6,13 | 5,88 | 6,00 | -2,04% | 4,26% | 164.400 |
| 20/03/1992 | 6,00 | 6,25 | 5,88 | 6,13 | +2,08% | 6,25% | 348.800 |
| 19/03/1992 | 6,38 | 6,38 | 6,00 | 6,00 | -5,88% | 5,88% | 77.000 |
| 18/03/1992 | 6,00 | 6,38 | 6,00 | 6,38 | +6,25% | 6,25% | 159.400 |
| 17/03/1992 | 6,63 | 6,63 | 6,00 | 6,00 | -8,57% | 9,43% | 88.600 |
| 16/03/1992 | 6,63 | 6,63 | 6,38 | 6,56 | +0,96% | 3,77% | 426.800 |
| 13/03/1992 | 6,13 | 6,63 | 5,88 | 6,50 | +10,64% | 12,24% | 542.200 |
| 12/03/1992 | 6,00 | 6,13 | 5,88 | 5,88 | -4,08% | 4,17% | 215.600 |
| 11/03/1992 | 6,00 | 6,13 | 5,75 | 6,13 | +6,52% | 6,25% | 256.800 |
| 10/03/1992 | 6,13 | 6,13 | 5,75 | 5,75 | +0,00% | 6,12% | 28.200 |
| 09/03/1992 | 6,00 | 6,00 | 5,75 | 5,75 | -4,17% | 4,17% | 30.400 |
| 06/03/1992 | 6,00 | 6,00 | 5,75 | 6,00 | +2,13% | 4,17% | 7.000 |
| 05/03/1992 | 6,00 | 6,00 | 5,75 | 5,88 | -4,08% | 4,17% | 33.200 |
| 04/03/1992 | 5,75 | 6,13 | 5,75 | 6,13 | +2,08% | 6,52% | 39.000 |
| 03/03/1992 | 5,75 | 6,00 | 5,75 | 6,00 | +0,00% | 4,35% | 25.600 |